-transparent.png){kind=logo}
After six years of home haemodialysis and two years of continuous ambulatory peritoneal dialysis a 59-year-old woman developed an aluminium-induced osteopathy, myopathy and normochromic anaemia. She was at first treated with intravenous, then peritoneal, deferoxamine, 1 g every other day. Before treatment, 15.8 micrograms aluminium (Al) had been eliminated daily, with a peritoneal clearance of 0.3 ml/min; after intravenous deferoxamine a mean of 774.3 +/- 102.3 micrograms Al was eliminated per day, after peritoneal deferoxamine 646.7 +/- 89.6 micrograms of Al per day, with a peritoneal clearance of 2.2 +/- 0.9 (intravenous) and 1.9 +/- 0.7 ml/min (intraperitoneal). After four months of deferoxamine administration, mostly intraperitoneally as an out-patient, the osteomalacia clearly improved, as did the myopathy and anaemia.
J Passlick, and
M Wilhelm, and
T Busch, and
B Grabensee, and
F K Ohnesorge
November 1985,
The Journal of pediatrics,
J Passlick, and
M Wilhelm, and
T Busch, and
B Grabensee, and
F K Ohnesorge
January 1980,
Annals of internal medicine,
J Passlick, and
M Wilhelm, and
T Busch, and
B Grabensee, and
F K Ohnesorge
July 1983,
Kidney international,
J Passlick, and
M Wilhelm, and
T Busch, and
B Grabensee, and
F K Ohnesorge
February 1987,
The American journal of medicine,
J Passlick, and
M Wilhelm, and
T Busch, and
B Grabensee, and
F K Ohnesorge
June 1984,
Kidney international,
J Passlick, and
M Wilhelm, and
T Busch, and
B Grabensee, and
F K Ohnesorge
January 1989,
Pediatric nephrology (Berlin, Germany),
J Passlick, and
M Wilhelm, and
T Busch, and
B Grabensee, and
F K Ohnesorge
November 1986,
Nihon Jinzo Gakkai shi,
J Passlick, and
M Wilhelm, and
T Busch, and
B Grabensee, and
F K Ohnesorge
January 1986,
La Revue de medecine interne,
J Passlick, and
M Wilhelm, and
T Busch, and
B Grabensee, and
F K Ohnesorge
November 1984,
The Journal of pediatrics,
J Passlick, and
M Wilhelm, and
T Busch, and
B Grabensee, and
F K Ohnesorge
January 1987,
Therapie,
